Get started
Celldex Therapeutics, Inc.Celldex Therapeutics, Inc.Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CLDX trade ideas

Celldex Stock Surge 28% On A Promising New Hives TreatmentCelldex Therapeutics ( NASDAQ:CLDX ) has recently emerged as a frontrunner in this arena, unveiling compelling results from its innovative treatment for chronic hives. The consequential findings have ignited a surge in investor enthusiasm, propelling the biotech stock to its highest point since October 2021. Celldex's ( NASDAQ:CLDX ) breakthrough revolves around its drug, barzolvolimab, which has demonstrated remarkable efficacy in patients grappling with moderate-to-severe chronic spontaneous urticaria—a condition characterized by persistent hives lasting at least six weeks. Notably, these individuals had previously shown resistance to traditional treatments such as antihistamines or other drugs. In a pivotal 12-week study, patients administered Celldex's( NASDAQ:CLDX ) barzolvolimab exhibited a statistically significant improvement in symptoms compared to those in the placebo group. This notable advancement underscores the drug's potential to address unmet medical needs in a population grappling with treatment-resistant chronic hives. One particularly striking outcome of the study is the achievement of "complete control" over hives in 37.5% of patients administered a high dose of barzolvolimab, compared to a mere 6.4% in the placebo group. Additionally, a significant proportion of patients experienced well-controlled disease, further accentuating the drug's therapeutic potential. Of particular significance is barzolvolimab's efficacy in patients previously unresponsive to Novartis and Roche's drug Xolair—a testament to its ability to address the needs of challenging-to-treat individuals. Moreover, the drug's favorable safety profile, characterized by a reduced incidence of neutropenia compared to previous studies, bodes well for its clinical viability and patient acceptance. In summary, Celldex's ( NASDAQ:CLDX ) groundbreaking advancements in chronic hives treatment mark a significant milestone in the field of biotechnology. With promising results and a compelling clinical profile, barzolvolimab heralds a new era of hope for patients and investors alike, positioning Celldex ( NASDAQ:CLDX ) as a key player in the quest for innovative medical solutions.
NASDAQ:CLDXLong
by DEXWireNews
💊Celldex Therapeutics (CLDX) Analysis: Positive Phase 2 StudyKey Highlights: Positive Phase 2 Study: Celldex Therapeutics revealed positive outcomes from a Phase 2 study of Barzolvolimab, focusing on patients with moderate to severe chronic spontaneous urticaria (CSU) refractory. Well-Tolerated and Favorable Safety Profile: Barzolvolimab demonstrated general well-tolerance and exhibited a favorable safety profile in the study. Transformative Potential: CEO Anthony Marucci highlighted the potential transformative role of Barzolvolimab as a treatment option for patients suffering from CSU. Technical Analysis: Support Level: The analysis suggests a support level above $35.00-$36.00, indicating a potential floor for price movements. Upside Target: The upside target is set in the range of $56.00-$58.00, reflecting positive expectations for Celldex Therapeutics. #CelldexTherapeutics #CLDX #Biopharmaceutical #ClinicalStudy #StockAnalysis #Investing
NASDAQ:CLDXLong
by Richtv_official
$CLDX PT 400 and higherCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
NASDAQ:CLDXLong
by BADQOMOCAWGOWLD
$CLDX can rise in the next daysContextual immersion trading strategy idea. Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $15,15 ; stop-loss — $13,54. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:CLDXLong
by KozakHlib
Signals for 12/06/2020Hey guys, me again. Let us take a look at some signals for Friday. EURUSD – On h1, you can see that the price was in a consolidation, and broke out with a bearish impulse. I’d say the price is either going to test the range’s support and fall down, put a target at 1.1250, or break through, test the support from above and go up until at least the top of the range, in which case that a target at 1.1380 and the second at 1.14 GBPUSD – we can see that the price tried to bounce from a support at 1.26, it tried for a false breakout, that’s a pretty bullish signal, so if the price holds above 1.2640, long with a target 1.27 AUDUSD – there’s an impulsive breakout out of a range, so think euro, either a pullback and bounce, or it goes back in then grows. Targets are 0.68 and 0.67 for short, and 0.70 for long. OIL – also pretty bearish. A reversal model occurred. I’m waiting for a pullback and fractal at 37, and then I’ll short with goals at 34 and 31.50. AAPL – let’s wait for the price to react to the level at 320-325. If the price bounces – long with a target at 350, and if it impulses below and pulls back, short with a target at around 300. FB – the price is in a range between 225 and 240. If it impulses down and holds below the range, short with a target at 220 and the second at 215. Also, if there’s a breakout, and then the price goes back inside the range, you can long with a goal at 240. CLDX – We can see important levels at 10, 8.50 and 7. If the price holds below 8.50, you can short with a goal at 7, and the second around 6. For more signals, subscribe to our youtube chanel www.youtube.com That’s about it. I hope you found this useful, and best of luck in trading.
NASDAQ:CLDX
by Horizon_Trading
insider-buys-celldex-therapeutics-sharesShares of Celldex Therapeutics Inc (NASDAQ:CLDX) moved higher by 1.5% from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, June 10 showed that Executive VP & CSO Keler Tibor bought 5,000 shares at an average price of $2.99. The transaction moved the executive's stake in Celldex Therapeutics Inc. to 7,357 shares. Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision. Insiders buying stock after a notable sell off can indicate an insider's long-term belief in the success of the company; insiders buying stock at new highs can be an indication the exec doesn't feel the stock is overvalued. Insiders who sell stock at new lows could be anticipating some capitulation moment. If the insider sells at new highs, it could point to the intention to "take some profit" and "lock in a gain. " Important Transaction Codes Investors prefer focusing on transactions which take place in the open market, indicated in the Form 4 with codes P for purchase and S for sale. if the transaction was an open-market transaction, that means that the insider made a concious decision for the company's stock moving forward. Transaction codes other than P or S are often viewed with less conviction as they are often not tied to a decision by the exec. As an example, transaction code C indicates the conversion of an option. Transaction code A indicates the insider may have been forced to sell shares in order to receive compensation the exec was promised upon being hired. finance.yahoo.com
NASDAQ:CLDX
by AlenCiken
$CLDX PRE MARKET MOVER ON POSITIVE DATA.********CLDX PRESENTED ENCOURAGING DADA AT THE ASCO ANNUAL MEETING ON JUNE 1st, WHICH HAS GOT THE ATTENTION OF INVESTORS PREMARKET, WITH A 15% POP, SPECULATIVE BUT POSSIBLY VERY REWARDING************ “We have observed intriguing clinical activity across a number of patients with similar gene mutation patterns in a disease that has extremely limited treatment options and a particularly poor prognosis,” said Dr. Bauman. “While the data are early, they are provocative and suggest the potential for a biomarker enrichment strategy that could change the standard of care for these patients. I look forward to the opportunity to obtain additional data on CDX-3379 in biomarker selected patient populations.” AVERAGE ANALYSTS PRICE TARGET $19 AVERAGE ANALYSTS RECOMMENDATION BUY CELLDEX THERAPEUTICS INC. Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.
NASDAQ:CLDX
by RedHotStocks